Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1825 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 |
filingDate |
2020-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_914b1fc0727f18807386d94c9020038c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76f2bd75ec5ba1bdcb10cd0e3f3ec2e5 |
publicationDate |
2020-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2020161341-A1 |
titleOfInvention |
Treatment of patients at risk of rapid progression of osteoarthritis |
abstract |
The invention pertains to active compounds, in particular FGF-18 compounds, for use in the treatment of patients affected with a cartilage disorder, preferably osteoarthritis (OA), in particular for the treatment of patients who are at risk of rapid progression of the disorder. |
priorityDate |
2019-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |